Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Pozuelo De Alarcon – page 194

3 275 clinical trials in Pozuelo De Alarcon, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pozuelo De Alarcon at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Pozuelo De Alarcon

Open in trial search

Study on JTT-861 for Patients with Heart Failure with Reduced Ejection Fraction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:JTT-861 monohydrochloride dihydrate
  • Sponsor:Akros Pharma Inc.

Study on IO102-IO103 and Pembrolizumab for Patients with Metastatic Lung, Head and Neck, or Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IO103 acetate
  • Sponsor:Io Biotech ApS

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effectiveness and Safety of Erdafitinib, Midazolam, and Metformin in Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:AstraZeneca AB

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma Not Well Controlled

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Pneumonia

Not recruiting

Study on AON-D21 for Patients with Severe Community-Acquired Pneumonia in Intensive Care

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aon-D21
  • Sponsor:Aptarion Biotech AG

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Pozuelo De Alarcon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple cancer types including bladder cancer, pancreatic adenocarcinoma, and non-small cell lung cancer. Studies evaluate novel combination therapies and targeted treatments.

  • Advanced solid tumors
  • Metastatic melanoma
  • Gastric cancer

Research includes immunotherapy approaches and antibody-drug conjugates for improved treatment outcomes.

02 Respiratory Medicine

Clinical investigations in respiratory conditions, including studies of RSV prevention in high-risk infants and novel treatments for uncontrolled asthma. Research focuses on innovative therapeutic approaches.

  • COVID-19 vaccine development
  • Respiratory infections
  • Inflammatory airway diseases

Studies evaluate both preventive measures and treatment interventions.

03 Neurological Disorders

Research targeting neurological conditions, with emphasis on Alzheimer's Disease and Multiple Sclerosis. Studies focus on disease-modifying therapies and novel treatment approaches.

  • Early-stage Alzheimer's treatment
  • Relapsing MS therapies
  • Neurodegeneration

Investigations aim to slow disease progression and improve patient outcomes.

04 Hematology

Studies in blood disorders including acute myeloid leukemia and immune thrombocytopenia. Research evaluates new therapeutic approaches and combination treatments.

  • Leukemia treatments
  • Myelodysplastic syndrome
  • Platelet disorders

Focus on improving survival rates and treatment efficacy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.